消除淋巴丝虫病全球方案中大规模药物管理的监测和流行病学评估：国家消除方案手册，第2版

Monitoring and epidemiological assessmentof mass drug administration in the globalprogramme to eliminate lymphatic filariasisA manual for national elimination programmes,second edition Monitoring and epidemiological assessment of mass drug administration in the global programme to eliminatelymphatic filariasis: a manual for national elimination programmes, second editionISBN 978-92-4-010595-9 (electronic version)ISBN 978-92-4-010596-6 (print version)© World Health Organization 2025Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes,provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestionthat WHO endorses any specifi c organization, products or services. The use of the WHO logo is not permitted. If youadapt the work, then you must license your work under the same or equivalent Creative Commons licence. If youcreate a translation of this work, you should add the following disclaimer along with the suggested citation: “Thistranslation was not created by the World Health Organization (WHO). WHO is not responsible for the content oraccuracy of this translation. The original English edition shall be the binding and authentic edition”.Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediationrules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).Suggestedcitation. Monitoring and epidemiological assessment of mass drug administration in the globalprogramme to eliminate lymphatic fi lariasis: a manual for national elimination programmes, second edition. Geneva:World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO.Cataloguing-in-Publication (CIP) data. CIP data are available at https://iris.who.int/.Sales, rights and licensing. To purchase WHO publications, see https://www.who.int/publications/book-orders. Tosubmit requests for commercial use and queries on rights and licensing, see https://www.who.int/copyright.Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables,figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtainpermission from the copyright holder. The risk of claims resulting from infringement of any third-party-ownedcomponent in the work rests solely with the user.General disclaimers. The designations employed and the presentation of the material in this publication do notimply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country,territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted anddashed lines on maps represent approximate border lines for which there may not yet be full agreement.The mention of specifi c companies or of certain manufacturers’ products does not imply that they are endorsedor recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissionsexcepted, the names of proprietary products are distinguished by initial capital letters.All reasonable precautions have been taken by WHO to verify the information contained in this publication.However, the published material is being distributed without warranty of any kind, either expressed or implied. Theresponsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable fordamages arising from its use. Contents Preface The Global Programme to Eliminate Lymphatic Filariasis (GPELF), launched by the World HealthOrganization (WHO) in 2000, had two strategic aims: to interrupt transmission of lymphaticfi lariasis (LF) through mass drug administration (MDA) and to alleviate the suffering of peopleaffected by the disease. Through collective efforts of national governments, WHO and partnersto implement the strategy, 21 countries have documented elimination of LF as a public healthproblem, more than 9.7 billion cumulative treatments have been delivered, and the estimatednumber of infections has been reduced by 74% globally(1, 2). MDA has been implemented in 71of the 72 countries considered to be endemic for the disease.Monitoring and evaluation has been essential in generating evidence for programme decisions,such as when to start and stop MDA. WHO guidance on monitoring and evaluation was revisedin 2005 and then again in 2011 to ensure the success of GPELF. In 2011, WHO published theMonitoring and epidemiological assessment of mass drug administration: a manual for nationallymphatic filariasis elimination programmes, which introduced transmission assessment surveys(TAS) to standardize the strategy for deciding t